Braunstein Scott, Chief Executive Officer, added 100,000 shares of Marinus Pharmaceuticals, Inc. (MRNS) to its portfolio at the rate of $1.25 per share valuing $125,000 on Dec 13. The insider has now 100,000 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $2.20, with a 2nd Resistance Point sitting at $2.27. Meanwhile, this company’s stock has a 1st Support Level at $2.07 and a 2nd Support Level at $2.01. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Marinus Pharmaceuticals, Inc. (MRNS) was $2.12. Marinus Pharmaceuticals, Inc. (MRNS) stock has gained $0.08, or 3.92%, in the past five days. In the last full month, these shares have gained $0.50, or 30.86%. In the past three months, this stock’s price has risen by $0.68, or 47.22%. This year-to-date, Marinus Pharmaceuticals, Inc. (MRNS) shares have lost -$0.04, or -1.85%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Marinus Pharmaceuticals, Inc. (MRNS) stock, 50% of short-term indicators suggest that these shares are a “ Buy .”
With 53,869 K shares outstanding, this company currently has a market capitalization of $114,202K. Marinus Pharmaceuticals, Inc. (MRNS) generates annual net income of -$36,730 K. This stock has generated a 1-Year Total Return of -39.94%, a 3-Year Total Return of 73.77%, and a 5-year Total Return of -82.64%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Marinus Pharmaceuticals, Inc. (MRNS) reported earnings of -$0.26 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.24 per share, representing a -0.02 difference and -8.33% surprise. In the previous quarter ending in 06/19, the reported earnings of -$0.24 represented a -0.02 difference from the consensus estimate calling for -$0.22 per share, which was a -9.09% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.22 per share. This estimate came from a total of 5 Wall Street Analysts. Of those market experts, the high estimate was -$0.18 and the low estimate was -$0.26. In the year-ago quarter, Marinus Pharmaceuticals, Inc. (MRNS) generated per-share earnings of -$0.24. If the analysts are correct about the current quarter’s earnings, the growth will be +8.33%.
Turning our focus now to insider trading activity, there have been 1 purchases (100,000 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 1 insider buys amounting to 100,000 shares and 0 insider sales amounting to 0 shares. In the past full year, 2 insider purchases were made (involving 131,662 shares) and 3 insider sell-offs equivalent to 34,845 shares.
Moving onto liquidity, Marinus Pharmaceuticals, Inc. (MRNS) has a Current Ratio of 10.70, a Quick Ratio of 10.70 and a Cash Ratio of 10.53.